Speakers

• 

  Laszlo Urban Global Head, Preclinical Safety Profiling Novartis Laszlo Urban is Global Head of Preclinical Safety Profiling at the Novartis Institutes for Biomedical Research (NIBR), Cambridge, Ma, and previously was the Deputy Head of the Novartis Institute for Medical Sciences in London, UK, an internationally recognized center of excellence for pain research. Read more...

• 

  Donna Dambach Director, Investigative Toxicology Genentech

• 

  Jeffrey Morgan Associate Professor of Medical Science & Engineering, Co-Director, Center for Biomedical Engineering Brown University Jeffrey Morgan, B.S. Syracuse, Ph.D. Harvard and postdoctoral training at the MIT/Whitehead Institute is an Associate Professor of Medical Science and Engineering at Brown University and Co-Director of the Center for Biomedical Engineering. Read more...

• 

  Donna Mendrick Director, Division of Systems Biology, National Centre for Toxicology Research FDA Dr. Donna L. Mendrick is the Director of the Division of Systems Biology at the National Center for Toxicology Research (NCTR), a research arm of the FDA. Read more...

• 

  Chuang Lu Associate Director, DMPK, Drug Safety and Disposition Millenium Dr. Chuang Lu is an Associate Director in DMPK at Millennium, The Takeda Oncology Company. He received his B.S. degree in Chemistry from the Beijing University in 1982 and his Ph.D. in the Environmental Chemistry from the American University of Washington, DC in 1992. Read more...

• 

  Andre Levchenko Associate Professor The John Hopkins University Prof. Levchenko got his B. S. and M.S. degrees at the Moscow Institute of Science and Technology, frequently referred to us as the Russian Caltech. He then crossed the Pond to study at Columbia University, culminating in a PhD in Bioengineering. Read more...

• 

  Dan Rock Principal Scientist, Pharmacokinetics and Drug Metabolism Amgen Dan Rock’s research activities include preclinical ADME and development of small molecules and antibody drug conjugates for inflammation and oncology. Research expertise include characterizing structure-function of drug metabolizing enzymes. Read more...

• 

  Guangqing Xioa Drug Metabolism and Pharmacokinetics Biogen Idec

• 

  John Davis Director of Investigative Toxicology, Drug Safety R&D Pfizer John Davis is presently the Director of Investigative Toxicology at Pfizer MA, leading a group of scientists in Drug Safety Research and Development responsible for nonclinical toxicology screening and mechanistic studies. Read more...

• 

  Ernie Bush Vice President, Collaborative Projects The Drug Safety Executive Council Dr. Bush has spent over 27 years working in the field of biomedical R&D most of which working in preclinical safety departments for major pharmaceutical companies. From 1992 to 2005 he worked at Hoffmann-La Roche, Inc. and for the last 5 years of that time he led their Non-Clinical Drug Safety Department. Read more...

• 

  David Cook Computational Biology Leader, Associate Director, Global Safety Assessment AstraZeneca Dr. Cook has a background in biochemistry and molecular biology with a PhD from Imperial Collage, London and three years of post-doctoral experience. Read more...

• 

  Hojae Bae Instructor Brigham and Women’s Hospital, Harvard Medical School Dr. Bae received his Bachelor’s degree in Genetic Engineering, Master’s degree in Bioengineering from Korea University and Ph.D. in Food Technology from Clemson University. Read more...

• 

  Hirdesh Uppal Scientist, Development Sciences Genentech Hirdesh Uppal, DVM, Ph.D., is currently a Scientist in Safety Assessment & Development Sciences at Genentech Inc. During Hirdesh's time in both biotechnology and pharmaceutical companies, he has excelled at developing scientific and strategic solutions to issues vexing the industry as well as conducting scientific research & translating the needs of the drug development into meaningful outcomes. Read more...

• 

  Hans Raabe V.P. Director, Laboratory Services Institute for In Vitro Sciences Mr. Raabe, Vice President and Director of Laboratory Services at the Institute for In Vitro Sciences (IIVS), received his BS degree in Zoology from the University of Maryland in 1984 and a MS in Biotechnology Management at the University of Maryland, University College in 1996. Read more...

• 

  Michael Aleo Research Fellow Pfizer Michael Aleo completed post-doctoral training as an NIH National Research Service Award Fellow at the University of Georgia after receiving a Ph.D. in Pharmacology and Experimental Therapeutics from The State University of New York at Buffalo. Read more...

• 

  Brooke Vandenbrink Scientist, Biochemistry and Biophysics Group, Department of Pharmacokinetics and Drug Metabolism Amgen Brooke VandenBrink research interests focus on developing in vitro kinetic models and methods to understand and predict the impact of cytochrome P450-dependent oxidation reactions on drug toxicity. Read more...

• 

  Mark Thiede Research Fellow Pfizer Since receiving his PhD from the University of Connecticut in Molecular Biology and Biochemistry in 1986, Y have spent my research career in the Pharmaceutical and Biotechnology industries. Read more...

• 

  Guoying Tai Investigator, Drug Metabolism and Pharmacokinetics GlaxoSmithKline Guoying Tai obtained a PhD in Medicinal Chemistry from the University of Washington, Seattle, under guidance of Dr. Allen Rettie. Her thesis research focused on the structure-function relationships of P450 enzymes (CYP2Cs) and CYP2C9 pharmacogenetics, in vitro and in vivo. Read more...

• 

  Chris Parker Chief Commercial Officer Cellular Dynamics International Chris Parker is responsible for sales, marketing and business development at Cellular Dynamics International. Mr. Parker brings more than 20 years of experience in the life science industry to CDI. Read more...